![](https://library.celltelligence.com/wp-content/uploads/2021/06/ASCO_Announcement.png)
$0
Obe-cel Demonstrates Best-In-Class Safety Profile in R/R B-ALL; Autolus Presents Positive Ph2 Results; ASCO 2023 Analysis 1
ASCO 2023 Analysis 1: Autolus presented topline data from obe-cel’s (CD19 CAR-T) pivotal Ph1b/2 FELIX study in adult r/r B-ALL. The abstract was included in the ‘Hematologic malignancies – leukemia, myelodysplastic syndrome, and allotransplant’ oral abstract session which integrated three abstracts that covered the landscape of CAR-Ts in the ALL space followed by a scientific discussion. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered: